While proteasome inhibition in cancer therapy is associated with cardiovascular side effects, there is potential for therapeutic applications in certain cardiac conditions, as restoring dystrophin complexes offers a new therapeutic strategy for muscular dystrophies such as Duchenne muscular dystrophy. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.